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Cell division is closely related to telomerase activity (hTERT mRNA). Lower expression of lymphocitic hTERT mRNA may easily
cause cell aging, which is not beneﬁcial to maintaining a durable lymphocyte division. To date, there is no study to investigate
IFNα therapy on hTERT mRNA expression in PBMCs of patients with chronic hepatitis B (CHB). We quantitatively detected
hTERT mRNA from study subjects and made each hTERT mRNA normalized (NhTERT mRNA). Mean NhTERT mRNA level
was lower in either CHB group, but it signiﬁcantly increased in IFNα-treated group compared with CHB control group, and a
longer duration of IFNα therapy could increase the level. Moreover, the mean NhTERT mRNA in subgroup with HBeAg loss was
signiﬁcantlyhigher than that in subgroup without. NhTERT mRNA was markedly correlated with CD3+ T lymphocyte count and
CD4+/CD8+ ratio. The results showed that IFNα therapy could upregulate the expression of hTERT mRNA in PBMCs.
1.Introduction
Telomeres are the terminal repeats of the chromosomes in
eukaryotic cells and continuously shorten with cell division.
Actingasa molecularclock,telomerescontrol thecapacityof
celldivisionandhaveacloserelationshipwithcellsenescence
[1]. Telomerase is an RNA-dependent DNA polymerase,
maintains the telomere length, and makes the cell achieve
unlimited proliferation capacity [2]. Telomerase consists of
two subunits, namely, functional RNA component (human
telomerase RNA, hTR) and human telomerase reverse
transcriptase catalytic subunit (hTERT) [3, 4]. hTR, which
is highly expressed in all tissues regardless of telomerase
activity, provides telomerase with the template for the
synthesis of telomeres, while the expression of hTERT is
in accordance with telomerase activity [5, 6]. Therefore,
the level of hTERT mRNA could reﬂect the activity of
telomerase. Germ cells and tumor cells often express higher
level of telomerase activity, whereas most of normal somatic
cells do not [7, 8], indicating that telomerase expression is
closely related to the cell diﬀerentiation and development.
The lymphocytesamong somatic cells, however, can produce
comparatively higher level of telomerase activity [9, 10],
which can keep telomere length of lymphocytes from
shortening, and thus play an important role in maintaining a
durable cell diﬀerentiation. If the lymphocytes express low
level of telomerase activity, telomere length will gradually
shorten with cell division and ﬁnally result in cell aging
and immune dysfunction, which has been conﬁrmed in
the researches of human immunodeﬁciency virus (HIV)
and chronic hepatitis B virus (HBV) infection [11, 12].
Up to now, little is known about the alteration of telom-
erase activity in lymphocytes during the antiviral therapy
on patients with chronic hepatitis B (CHB). We herein
quantitatively detected the expression of hTERT mRNA in
peripheral blood mononuclear cells (PBMCs) from CHB
patientswho received interferon alpha (IFNα) treatment and
attempted for the ﬁrst time to study the possible relationship
between the immunomodulator and the telomerase activity
in PBMCs.2 Clinical and Developmental Immunology
2.Materialsand Methods
2.1. Study Subjects. All investigated CHB patients, who met
the criteria of the guidelines of prevention and treatment for
chronic hepatitis B issued by Chinese Society of Hepatology
[13], were those hospitalized in the Fifth People’s Hospital
of Suzhou during the year of 2009. The study was composed
of three groups, namely, IFNα-treated group, CHB control
group, and healthy control group. None of the patients in
IFNα-treated group and CHB control group received any
immunomodulator treatment including immune enhancers
or immunosuppressive agents, as well as antiviral agents
including nucleoside/nucleotide analogues for at least 6
monthsbeforeIFNαtherapyinitiated.Allpatientswereruled
out the coinfection with hepatitis A, C, D, or E viruses, as
well as other liver damages caused by alcohol, drug, autoim-
munity, and so forth. Healthy control group consisted of our
10 volunteer colleagues, who had normal liver function and
were tested negative for the serum immunological markers
of hepatitis B, C, and D virus infection. All subjects gave
their voluntary informed consents about the study, and the
research protocol was approved by the ethics committee
of the Fifth People’s Hospital of Suzhou. In IFNα-treated
group, all the patients were given conventional IFNα-2b
5MU intramuscular injection once a day for 2 weeks, and
then were injected every other day for the total duration of
1 year. During the treatment, liver function and blood cell
counts were tested monthly, and HBV serological markers
a n dH B VD N Al o a dw e r et e s t e de v e r y3m o n t h s .
2.2. Baseline Clinical Tests. In IFNα-treated group and CHB
control group, all the baseline HBV serological mark-
ers (Abbott Ireland, Diagnostics Division, Sligo, Ireland),
HBV DNA loads (Shanghai Shenyou Technology Co. Ltd,
Shanghai, China), HBV genotypes (Shanghai ZJ Biological
Technology Co. Ltd, Shanghai, China), and the routine
biochemical tests, including liver function, kidney function,
thyroid function, blood sugar, and peripheral blood cell
counts, and so forth were detected. Lymphocyte subsets (BD
Biosciences, San Jose, CA, USA) in 28 cases of IFNα-treated
group and 26 cases of CHB control group were detected
at baseline, and the lymphocyte subsets were retested in 26
patients after given IFNα treatment for at least 6 months.
2.3. PBMCs Sample Collection. 5mL of heparin-anticoag-
ulated peripheral blood was collected from each subject.
Among them, the samples from IFNα-treated group were
collectedat the time of 6,9, and 12months oftreatment, and
those from CHB control group were collected on the second
day of the patient’s hospitalization. PBMCs were isolated
by standard Ficoll density-gradient centrifugation and then
washed with 0.01M phosphate buﬀer solution (PBS). After
centrifugation, about 5 × 106 cells were gathered for each
sample and kept frozen at −80◦Cu n t i lt h es a m p l e sw e r e
used.
2.4. Total Cellular RNA Extraction. Total cellular RNA was,
respectively, extracted using BIOZOL (Hangzhou Bioer
Technology Co. Ltd, Hangzhou, China) according to the
manufacturer’s instruction. Brieﬂy,each PBMCs sample was,
respectively, precipitated and lysed, and then the cellular
RNAwas isolated, precipitated, washed, and ﬁnally dissolved
in 30μL of RNase-free water. The integrity of RNA was
determined, respectively. The samples with obvious 28S and
18SrRNA components were used for the following study.
2.5. Detection of hTERT mRNA and β-actin mRNA. hTERT
mRNA was quantitatively detected by real-time reverse
transcription polymerase chain reaction (RT-PCR) (AB
Applied Biosystems 7300 real-time PCR System, USA),
using the quantiﬁcation kit (Hangzhou Bioer Technology
Co. Ltd, Hangzhou, China) conducted in accordance with
the product instruction. Total reactive volume was 40μL
and contained 4μLo fR N As a m p l e( 1 μgo rs o ) .A f t e r4 0
cycles of reaction, the quantitative results could be obtained
automatically from PCR detection system, and the unit of
hTERT mRNA is copies/ml in terms of the kit indication. In
order to exclude all the possible factors inﬂuencing the com-
parison of hTERT mRNA levels among diﬀerent samples, β-
actin was used as internal control and its mRNA was also
quantitativelydetectedbyreal-time RT-PCRforeachsample,
using the quantiﬁcation kit (Shanghai Genepharma Co. Ltd,
Shanghai,China)performedaccordingtothemanufacturer’s
instruction. The results also could be obtained automatically
and the unit is copies/μl. Therefore, a normalized hTERT
m R N A( N h T E R Tm R N A )c o u l db eo b t a i n e df o re a c h
sample; that is, NhTERT mRNA could be calculated as the
copies of target gene hTERT mRNA divided by the copies of
its internal control gene β-actin mRNA.
2.6.Statistical Analysis. Adescriptiveanalysis ofthevariables
collected from each subject was performed. Continuous
variables were shown as median values and the dispersion
measurement as range values. The chi-squared test and
t-test were used for analysis of the selected variables.
Mean NhTERT mRNA level was presented as mean ± SD.
The diﬀerences between two groups were compared using
independent-samples t-test and multiple groups using one-
way analysis of variance. Spearman rank correlation analysis
was used for bivariate correlation analysis. A probability
value was determined using two-sided statistical test. P<. 05
was considered to be statistically signiﬁcant. All statistical
analyses were performed using SPSS version 13.0 for win-
dows (SPSS, Chicago, IL, USA).
3.Results
3.1. Baseline Characteristics of the Study Groups. The clinical
characteristics of the three groups were listed in Table 1.
Gender and age were listed for all groups. HBeAg status,
aniline aminotransferase (ALT) levels, HBV DNA levels, and
HBV genotypes were listed for all CHB patients. The counts
of CD3 and the ratio of CD4+/CD8+ were listed for 28
patients in IFNα-treated group and 26 patients in CHB
control group. There was/were no signiﬁcant diﬀerence(s)
for these baseline characteristics among the study groups.Clinical and Developmental Immunology 3
Table 1: Clinical baseline characteristics of the study groups.
IFNα-treated
Group
(n = 37)
CHB control group
(n = 36)
Healthy control
group
(n = 10)
P-value
Male 25 (67.6) 28 (77.8) 6 (60) .56
Median age in year (range) 27.3 (20–48) 28.6 (23–55) 30.6 (24–45) .68
No. of HBeAg + patients 31 (83.8) 25 (69.4) N/A .65
Median ALT (range), IU/L 148.3 (83–288) 132.8 (83–352) N/A .61
Median HBV DNA load
(range), log copies/ml 7.6 (5.2–9.4) 7.2 (4.8–8.7) N/A .72
HBV genotype (no. of
patients)
Type B (11) Type B (8) .47
Type C (23) Type C (25) N/A .51
Other (3) Other (3) .97
Median CD3 count
(range), 106 cell/L 1138 (971–1493) 1278 (856–1387) N/A .72
Median ratio of CD4/CD8
(range) 1.72 (1.13–2.57) 1.58 (1.26–2.63) N/A .51
Note. Date are no. (%) of patients, unless otherwise indicated; HBeAg+: positive for hepatitis B e antigen; ALT: alanine aminotransferase; HBV: hepatitis B
virus; N/A, not applicable.
3.2.IFNαTherapyand Responses. InIFNα-treatedgroup,the
results of change in biochemical, immunological, and viro-
logical indices were evaluated after the beginning of antiviral
therapy for at least 6 months. In this study, there were 11
patients evaluated at the time of treatment for 6 months, 14
patients for 9 months, and 12 patients for 12 months. In the
beginning of IFNα therapy, the varying degrees of ﬂu-like
symptoms occurred, the count of neutrophils and platelets
decreased in some patients, and no severe adverse events
which led to IFNα dose reduction or antiviral interruption
happened. The biochemical, virological, and immunological
responses to IFNα were as follows: ALT normalization
(<40IU/mL) in 23 cases, ALT elevation (≥40IU/mL) in 14
cases; HBV DNA load <3log/mL in 18 cases, HBVDNAload
≥3log/mLin19cases;andamong31casesofHBeAgpositive
patients, 14 cases with HBeAg loss, and 17 still with positive
serum HBeAg.
3.3. Comparison of Mean NhTERT mRNA Levels. Each level
of NhTERT mRNA in PBMCs of the three groups could
be seen in Table 2.A m o n gt h et h r e eg r o u p s ,t h em e a n
NhTERT mRNA was 1.042 × 10−3 in healthy control group,
0.959 × 10−3 in IFNα-treated group, and 0.857 × 10−3 in
CHB control group, respectively. The compared results were
shown in Figure 1. There were no remarkable diﬀerences
between diﬀerent gender groups, genotype groups, as well
as HBeAg positive and negative groups (P = .753, P =
.664, and P = .587, resp.). Regarding the duration of IFNα
treatment on the inﬂuence of mean NhTERT mRNA levels,
Figure 2 showed that the patients with longer duration of
IFNα treatment had higher levels of NhTERT mRNA in
PBMCs.
3.4. Relationship of NhTERT mRNA with Clinical Character-
istics. Spearman rank correlation analysis showed that the
NhTERT mRNA expression was not associated with age in
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No.
Mean NhTERT
mRNA level
(×10−3)
t- valueP - value
Healthy control group 10 1.042 ± 0.118
4.028 <.001∗ CHB control group 36 0.857 ± 0.131
2.107 .041∗∗ IFNα treated group 37 0.959 ± 0.109
3.605 .001#
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Figure 1: Mean NhTERT mRNA levels in the study groups.
all subjects (r =− .059, P = .594, n = 83), and neither
was with ALT in all CHB patients (r =− .116, P = .329,
n = 73). There was signiﬁcant relationship between the
expression of NhTERT mRNA and the count of CD3+ T
lymphocytes (r = .304, P = .026, n = 54) as well as the
ratio of CD4+/CD8+ (r = .285, P = .041, n = 54) when
the 54 patients with lymphocyte subset test were taken into4 Clinical and Developmental Immunology
Table 2: NhTERT mRNA levels in PBMCs of all investigated
subjects.
No.
IFNα treated
group (n = 37)
NhTERT mRNA
CHB control
group (n = 36)
NhTERT mRNA
Healthy control
group (n = 10)
NhTERT mRNA
1 0.911 × 10−3 0.775 × 10−3 1.094 × 10−3
2 0.985 × 10−3 0.930 × 10−3 1.204 × 10−3
3 1.016 × 10−3 0.901 × 10−3 1.017 × 10−3
4 0.985 × 10−3 0.673 × 10−3 1.260 × 10−3
5 1.096 × 10−3 0.792 × 10−3 0.959 × 10−3
6 1.103 × 10−3 0.885 × 10−3 1.017 × 10−3
7 0.990 × 10−3 0.693 × 10−3 0.902 × 10−3
8 0.989 × 10−3 0.989 × 10−3 1.069 × 10−3
9 1.002 × 10−3 0.583 × 10−3 0.992 × 10−3
10 1.000 × 10−3 0.841 × 10−3 0.906 × 10−3
11 0.983 × 10−3 0.749 × 10−3
12 1.058 × 10−3 0.927 × 10−3
13 0.914 × 10−3 0.980 × 10−3
14 0.994 × 10−3 0.736 × 10−3
15 0.989 × 10−3 1.010 × 10−3
16 1.034 × 10−3 0.875 × 10−3
17 1.042 × 10−3 0.757 × 10−3
18 0.991 × 10−3 0.954 × 10−3
19 1.061 × 10−3 0.907 × 10−3
20 1.220 × 10−3 1.001 × 10−3
21 0.924 × 10−3 0.880 × 10−3
22 0.952 × 10−3 0.887 × 10−3
23 0.994 × 10−3 1.088 × 10−3
24 0.800 × 10−3 0.790 × 10−3
25 0.980 × 10−3 0.708 × 10−3
26 1.018 × 10−3 0.941 × 10−3
27 0.809 × 10−3 0.917 × 10−3
28 0.967 × 10−3 0.655 × 10−3
29 1.088 × 10−3 0.593 × 10−3
30 0.791 × 10−3 0.916 × 10−3
31 0.932 × 10−3 0.942 × 10−3
32 0.717 × 10−3 1.088 × 10−3
33 0.751 × 10−3 0.702 × 10−3
34 0.863 × 10−3 0.968 × 10−3
35 0.943 × 10−3 0.965 × 10−3
36 0.770 × 10−3 0.859 × 10−3
37 0.809 × 10−3
accountasatotalandanalyzed.Andamongthem,26patients
in IFNα-treated group had their lymphocyte subset retested,
and further analysis showed thatthe levelofNhTERT mRNA
was much more signiﬁcantly associated with the count of
CD3+ Tlymphocytes(r = .572,P = .003,n = 26)andsowas
withtheratioofCD4+/CD8+ (r = .527,P = .008,n = 26).In
addition, there were 25 patients with detectable serum HBV
DNA in IFNα treated group (≥2.7log copies/mL based on
the lowest limit of the RT-PCR kit), and analysis showed that
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6-month treatment 11 0.904 ± 0.117
1.016 .320∗ 9-month treatment 14 0.943 ± 0.077
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Figure 2: Mean NhTERT mRNA levels in groups with diﬀerent
duration of IFNα treatment.
NhTERT mRNA level was not signiﬁcantly correlated with
HBV DNA load whether in CHB control group (r = .230,
P = .176, n = 36) or in IFNα treated group (r =− .209,
P = .316, n = 25).
3.5. Relationship between NhTERT mRNA and Antiviral
Responses. The patients in IFNα-treated group were further
divided into three subgroups in terms of their biochemical,
virological, and immunological responses to IFNα therapy.
We found that the mean NhTERT mRNA level was signiﬁ-
cantlyhigherinHBeAglosssubgroupcomparedwithHBeAg
positive subgroup (P = .015), and especially, the level in
HBeAg loss subgroup was comparable to that in healthy
control group (P = .479). The mean NhTERT mRNA level
was higher in HBV DNA load ≤3log subgroup compared
with HBV DNA load >3log subgroup but did not reach
statistical signiﬁcance (P = .059). There was no signiﬁcant
diﬀerence between ALT normal and abnormal subgroups
(P = .249, Table 3).
4.Discussion
Lymphocytes are indispensable components for the host
immune response, and the enough number of the cells is
the basic precondition to maintain the normal immune
function. During the typical immune reaction, the prolifer-
ation of lymphocytes increases 105-106 fold compared withClinical and Developmental Immunology 5
Table 3: Comparisonof mean NhTERT mRNA levels between IFNα-treated subgroups.
ALT(IU/L) HBV DNA (log copies/mL) HBeAg status∗
<40 ≥40 <3l o g ≥3l o g e - A g( + ) e - A g( −)
No. 23 14 18 19 17 14
Mean NhTERT 0.967 1.007 1.011 0.950 0.910 1.010
mRNA level (×10−3) ±0.105 ±0.095 ±0.084 ±0.105 ±0.111 ±0.100
t-value 1.172 1.955 2.595
P-value .249 .059 .015
Note. ∗subgroup: 31 cases of HBeAg positive CHB; e-Ag (+): without HBeAg loss; (−): with HBeAg loss.
the resting state [14]. The cellular replicative life span in
normal somatic cells is ﬁnite. However, lymphocytes are the
rare somatic cells to obtain the relatively enduring ability
to divide, which may be, to some extent, associated with
lymphocytic telomere length, because the cell replicative
capacity depends largely on their telomere length. The
length of human telomeric repeats is 5–15kb [15, 16]
and shortens gradually with cell division. When telomeres
shorten to a certain limit, cells cannot replicate anymore
and chromosomal instability and cell senescence will ensue
[17]. The shortening telomere length of lymphocytes is a
sign of immune senescence [18]. Telomerase can synthesize
the repeat sequence TTAGGG at the telomeric ends and
which can resist the shortening of telomere length; so the
lymphocytes with higher telomerase activity should have
more durable ability for cell division and proliferation.
The researches have conﬁrmed that the antigen-speciﬁc
T lymphocytes can maintain telomere length so long as
telomerase activity is high [19, 20]. In the study of HIV-
infected patients, the expression of hTERT mRNA in CD4+
T lymphocytes was found signiﬁcantly decreased [21, 22],
which could lead to a reduced telomerase activity and
shortened cell life expectancy and thus result in a limited
proliferation of CD4+ T cell clones. That the lymphocytes
possess a lower hTERT mRNA level may also be responsible
for the decreasing number of CD4+ T lymphocytes besides
the HIV direct injury to the cells. Therefore, based on the
performed studies, we can ﬁnd that a certain relationship
exists between the telomerase activity and the immune cells.
Inourstudy,we quantitativelydetectedhTERTmRNAin
PBMCsfrom CHBpatientsand healthy controls. However, it
was not suitable to directly compare the hTERT mRNA level
amongthesubjectsmainlybecauseofthetworeasons:(1)the
count of PBMCs was not absolutely equal for each sample;
(2) the RNA concentration was diﬃcult to keep equal in
the management of cellular RNA extraction for each sample.
Therefore, in order to reasonably analyze the data, β-actin, a
house-keeping gene which expresses invariably in all tissues
and cells, was used as internal control and its mRNA was
also quantitatively detected. So a relative comparison value,
NhTERT mRNA, was obtained, and which reﬂects a relative
level of hTERT expression as one copy of β-actin mRNA is
expressed inPBMCs. The relative value should be stable fora
certain individual and could be analyzed reasonably among
the subjects. Of course, it would be much better to directly
analyze hTERT mRNA if the count of isolated lymphocytes
and the concentration of extracted RNA could be obtained
equally for each subject. From our data, we found that the
expression of NhTERT mRNA in PBMCs of CHB patients
presented signiﬁcantly positive correlation with both the
count of CD3+ Tl y m p h o c y t e sa n dt h er a t i oo fC D 4 +/CD8+,
and moreover, the correlation extent seemed to be more
remarkable for these indicesin IFNα-treatedgroup.NhTERT
mRNA level did not show the signiﬁcant correlation with
the age of subjects, patient’s ALT level, and the load of
HBV DNA, respectively. The mean level of NhTERT mRNA
was also not signiﬁcantly diﬀerent among the diﬀerent HBV
genotype groups. The results showed that the lymphocytic
telomerase activity was closelyassociated with the number of
lymphocytes and the immune function in CHB patients.
In vitro studies, it had been found that the telomerase
activity signiﬁcantly increased when the peripheral blood
T lymphocytes were stimulated with mitogens, such as
phytohemagglutinin (PHA) or phorbol ester (PMA), anti-
CD3 antibody, interleukin-2 (IL-2), and other cytokines,
but signiﬁcantly decreased telomerase activity could be
caused by use of hydrocortisone stimulating PBMCs [6, 23–
25], indicating that immune regulators can exert diﬀerent
impacts on the expression of telomerase activity in lym-
phocytes. Interferon is an important immunomodulator for
upregulating host immunity and thus becomes one of the
importantantiviraldrugsapprovedforthetreatmentofCHB
across the world [26]. In this study, we found that the mean
NhTERT mRNA level was signiﬁcantly lower in each CHB
patient group than in healthy control group, which was in
agreement with the result studied by Satra et al. [12]. The
mean level of NhTERT mRNA in IFNα-treated group was
remarkablyhigherthanthatinCHBcontrolgroup,andmore
interestingly, a higher mean level of NhTERT mRNA was
shown in the patients with longer duration of IFNα treat-
ment. According to the stratiﬁed analysis of biochemical,
virological, and immunological responses in IFNα-treated
group, we found that the mean level of NhTERT mRNA in
HBeAglosssubgroupwassigniﬁcantlyhighercomparedwith
the subgroup without, and furthermore, the level in HBeAg
loss subgroup was comparable to that in healthy control
group; an increased level of NhTERT mRNA could be seen
in HBV DNA undetectable subgroup but it did not reach
to the statistical signiﬁcance as compared with HBV DNA
detectable subgroup; the mean levels were not of signiﬁcant
diﬀerence between ALT normal and abnormal subgroups.
Theresultsdemonstratedthatalowertelomeraseactivitywas6 Clinical and Developmental Immunology
expressed in PBMCs of CHB patients, and IFNα treatment
could obviously upregulate the expression of hTERT mRNA.
In view of the multiple cell components existed in PBMCs,
therefore we will further investigate whether the change of
hTERT expression is derived from the B cells or from the
T cells or both, and furthermore, it is also very important
to know whether the change is involved in the na¨ ıve cells or
memory cells, and so forth.
In addition, we can ﬁnd that there exists a close relation-
ship betweentheexpressionofhTERTmRNAinPBMCsand
IFNα treatment in CHB patients, but the exact mechanism
of IFNα treatment leading to an increased hTERT mRNA
expression is not yet clear. In some researches with tumor
cell lines, interferon could both inhibit the expression of
hTERT mRNA in leukemia cells or melanoma cells and
increase its expression in certain tumor cell lines [27–29].
Recently, Hrdlickova et al. [30] conducted a research on
the immune cells, and they found that interferon regulatory
factor 4 and 8 correlated with the activation of telomerase
promoter in macrophage cell lines, which could increase the
transcription of macrophage telomerase and upregulate its
activity. In our study, it is not clear whether there is a similar
mechanism involved in the increased expression of hTERT
mRNA in PBMCs during IFNα therapy. However, no matter
what the mechanism for the increase of hTERT expression
in PBMCs is, we think that the mechanism to upregulate the
immune function in CHB patients treated with IFNα should
at least include the role played by the increased activity of
lymphocytic telomerase besides the eﬀects of immune cells
and cytokines known previously [31], because lymphocytes
with higher telomerase activity attributed to IFNα treatment
can resist the telomeric erosion, and thus lymphocytes
will get a longer life span and more durable ability for
cell division, which is the basic precondition for CHB
patients to acquire a normally immune response to HBV
infection.
In conclusion, we found that the telomerase activity in
PBMCs was closely correlated with the total lymphocyte
number and the immune function in CHB patients. The
expression of telomerase activity in PBMCs of patients with
chronic HBV infection was signiﬁcantly lower than that
in healthy individuals, and IFNα treatment could, at least
in part, elevate the reduced telomerase activity in PBMCs,
particularly in those who achieved HBeAg loss. Therefore,
the increased telomerase activity in PBMCs of CHB patients
due to IFNα therapy could extend the lymphocyte life span,
maintain the durable cell division, and promote the immune
function, which may be involved in a novel mechanism for
IFNα antiviral therapy.
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